International AIDS Vaccine Initiative & Serum Institute of India
3 shared events · Importance 3 · Last updated Jun 03, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Tech
International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative (IAVI) received an initial $3.2 million from CEPI to develop a single-dose Bundibugyo vaccine candidate using technology similar to Merck's Ervebo.
Serum Institute of India: The Serum Institute of India is manufacturing a vaccine candidate developed by the University of Oxford, receiving up to $8.6 million from CEPI for its development.
May 22, 2026 · 36 articles
Tech
International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative is developing rVSV Bundibugyo, a single-dose vaccine candidate seen as promising by the World Health Organization, though it is not yet ready for trials.
Serum Institute of India: The Serum Institute of India collaborated with the University of Oxford to develop ChAdOx1 Bundibugyo, a vaccine candidate for the Ebola Bundibugyo strain.
May 28, 2026 · 6 articles
Accidents
International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative is developing a Bundibugyo-specific version of a vaccine using a platform similar to Merck & Co.'s Ervebo vaccine, contributing to the search for a treatment.
Serum Institute of India: The Serum Institute of India is manufacturing doses of a vaccine candidate built on the University of Oxford/AstraZeneca platform, which could be used for clinical trials against the Bundibugyo ebolavirus.
May 18, 2026 · 505 articles
NEWSDESK
Explore this relationship live
Track how International AIDS Vaccine Initiative and Serum Institute of India interact across events, view sentiment trends, and discover connected entities.
Open Dashboard